The development of human diseases is highly complex. Directly using humans as experimental subjects to investigate disease mechanisms is limited by ethical concerns and safety risks, often slowing progress in biomedical research.
Animal models provide a powerful alternative by allowing researchers to manipulate variables that are impossible or difficult to control in humans. These models enable systematic observation, mechanistic studies, and translational comparisons with human diseases—greatly accelerating the understanding of disease progression and the development of preventive and therapeutic strategies.
Yeasen Biotechnology offers a comprehensive portfolio of animal disease modeling reagents, covering inflammatory, metabolic, neurological, cardiovascular, and cancer models. A detailed selection guide is provided below.
Disease Model Product Selection Guide
|
Model |
Modeling Reagent |
Solvent |
Model Validation |
|
Ulcerative Colitis |
Distilled water |
H&E staining (Cat# 60524ES) Fecal occult blood test (Cat# 60403ES) AB-PAS staining (Cat# 60534ES) 5-ASA (Cat# 60317ES) 6-Sulfasalazine (Cat# 60320ES) 7-5-Fluorouracil (Cat# 51412ES) |
|
|
Acute Liver Injury |
TAA (Cat# 60395ES) |
Sodium chloride (Cat# 60372ES) |
H&E staining (Cat# 60524ES) Masson staining (Cat# 60532ES) |
|
Hemolytic Anemia |
APH (Cat# 60396ES) |
Sodium chloride (Cat# 60372ES) |
H&E staining (Cat# 60524ES) |
|
Pancreatitis |
Sodium taurocholate (Cat# 60398ES) |
— |
H&E staining (Cat# 60524ES) |
|
Sodium chloride (Cat# 60372ES) |
|||
|
L-Arginine (Cat# 61302ES) |
— |
||
|
Diabetes |
STZ (Cat# 60256ES) |
Citric acid monohydrate (Cat# 60347ES) Sodium citrate dihydrate (Cat# 60348ES) |
H&E staining (Cat# 60524ES) |
|
Alloxan monohydrate (Cat# 60331ES) |
Sodium chloride (Cat# 60372ES) |
H&E staining (Cat# 60524ES) |
|
|
Parkinson’s Disease |
Rotenone (Cat# 60393ES, powder / 60394ES, solution) |
DMSO (Cat# 60313ES)Sodium chloride (Cat# 60372ES) |
— |
|
MPTP (Cat# 60388ES, powder / 60387ES, solution) |
Sodium chloride (Cat# 60372ES) |
— |
|
|
Oral Cancer |
4-NQO (Cat# 60392ES) |
Distilled water |
H&E staining (Cat# 60524ES) |
|
Gastric Cancer |
MNNG (Cat# 60397ES) |
DMSO (Cat# 60313ES) |
H&E staining (Cat# 60524ES) |
|
Hypertension |
L-NAME hydrochloride (Cat# 52302ES) |
Distilled water / Sodium chloride(Cat# 60372ES) |
H&E staining (Cat# 60524ES) |
|
Angiotensin II (human) (Cat# 54041ES) |
|||
|
Deoxycorticosterone acetate (Cat# 54344ES) |
|||
|
Rheumatoid Arthritis |
Complete Freund’s Adjuvant (CFA) (Cat# 60718ES) |
Distilled water
|
H&E staining (Cat# 60524ES) |
|
Incomplete Freund’s Adjuvant (IFA) (Cat# 60719ES) |
High-Quality DSS (Dextran Sulfate Sodium) Selection Guide
|
Cat. No. |
Molecular Weight |
Colitis Model |
Nanomaterials |
Molecular Biology |
Antiviral |
Anticoagulant |
Lipid Removal |
Cell Proliferation |
Polysaccharide Assay |
Anti-apoptosis |
|
60316EI |
1,500 |
— |
— |
— |
√ |
— |
— |
— |
— |
— |
|
60316EH |
3,000 |
— |
— |
— |
√ |
— |
— |
— |
— |
— |
|
60316EG |
5,000 |
— |
√ |
— |
√ |
√ |
— |
√ |
— |
√ |
|
60316EF |
10,000 |
— |
√ |
√ |
√ |
— |
— |
— |
— |
— |
|
60316ED |
15,000 |
— |
— |
— |
√ |
— |
— |
— |
— |
— |
|
60316EC |
20,000 |
— |
√ |
√ |
— |
√ |
— |
— |
— |
— |
|
60316ES |
36,000–50,000 |
√ |
— |
— |
√ |
— |
— |
— |
— |
— |
|
60316EB |
50,000 |
— |
— |
√ |
— |
√ |
√ |
√ |
— |
— |
|
60316EA |
500,000 |
— |
√ |
√ |
— |
√ |
— |
— |
— |
— |
Customer Case Studies
- Sulfur content: 16–20%
- Free sulfur: <0.2%
- Efficient and safe simulation of human ulcerative colitis (UC)
 Figure 1. H&E Staining Results of Colitis |
Case 1 – UC Model Institution: A* University Animal: C57BL/6 mice Protocol: 3% (w/v) DSS in drinking water for 7 days Reference: J Nutr Biochem, 2020
|
Figure 2. H&E Staining Results of Colorectal Cancer |
Case 2 – Colitis-Associated Cancer Institution: B* University Animal: BALB/c mice Protocol: l AOM 10 mg/kg l 2.5% DSS for 1 week → water for 2 weeks l Repeat DSS cycle ×3 Reference: Front Pharmacol, 2020 DOI: 10.3389/fphar.2020.586885 |
- Decapeptide structure
- Purity (HPLC): ≥97%
 Figure 3. H&E Staining Results of Pancreas |
Case 3 – Severe Acute Pancreatitis Institution: School of Medicine, C* University Animal: BALB/c mice Protocol: Intraperitoneal injection of cerulein (50 μg/kg) every hour ×7 LPS (10 mg/kg) at final injection Reference: EBioMedicine, 2022 DOI: 10.1016/j.ebiom.2022.103959 |
3. STZ (Cat# 60256ES)
- Streptozotocin
- Purity (HPLC): ≥98%
 Figure 4. H&E Staining Results of Various Organs |
Case 4 – Diabetes Model Institution: D* University Reference: ACS Applied Materials & Interfaces, 2022 DOI: 10.1021/acsami.1c24569 |
Selected Customer Publications
[1]. Zhao L, Wang F, Cai Z, et al. Improving drug utilization platform with injectable mucoadhesive hydrogel for treating ulcerative colitis. Chem Eng J. 2021;424:130464. doi:10.1016/j.cej.2021.130464 (IF = 16.744)
[2]. Tong L, Hao H, Zhang Z, et al. Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota. Theranostics. 2021;11(17):8570–8586. doi:10.7150/thno.61307 (IF = 11.556)
[3]. Li Y, Dong J, Xiao H, et al. Gut commensal-derived valeric acid protects against radiation injuries. Gut Microbes. 2020;12(1):1–18. doi:10.1080/19490976.2020.1802824 (IF = 10.245)
[4]. Gan J, Liu Y, Sun L, et al. Orally administrated nucleotide-delivery particles from microfluidics for inflammatory bowel disease treatment. Appl Mater Today. 2021;25:101231. doi:10.1016/j.apmt.2021.101231 (IF = 10.041)
[5]. Dong J, Li Y, Xiao H, et al. Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models. Cell Rep. 2021;37(12):109886. doi:10.1016/j.celrep.2021.109886 (IF = 9.423)
[6]. Xi Z, Ahmad E, Zhang W, et al. Dual-modified nanoparticles overcome sequential absorption barriers for oral insulin delivery. J Control Release. 2022;342:1–13. doi:10.1016/j.jconrel.2021.11.045 (IF = 9.776)
[7]. Xu Z, Liu Y, Ma R, et al. Thermosensitive hydrogel incorporating Prussian blue nanoparticles promotes diabetic wound healing via ROS scavenging and mitochondrial function restoration. ACS Appl Mater Interfaces. 2022;14(12):14059–14071. doi:10.1021/acsami.1c24569 (IF = 9.229)
[8]. He R, Shi J, Xu D, et al. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Cancer Lett. 2022;538:215693. doi:10.1016/j.canlet.2022.215693 (IF = 8.679)
[9]. Zhang L, Shi J, Du D, et al. Ketogenesis acts as an endogenous protective programme to restrain inflammatory macrophage activation during acute pancreatitis. EBioMedicine. 2022;78:103959. doi:10.1016/j.ebiom.2022.103959 (IF = 8.143)
[10]. Zhang X, Gao X, Yi X, et al. Multi-targeting inulin-based nanoparticles with cannabidiol for effective prevention of ulcerative colitis. Mater Today Bio. 2024;25:100965. doi:10.1016/j.mtbio.2024.100965 (IF = 8.2)